• Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO

  • Dec 22 2023
  • Duración: 35 m
  • Podcast

Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO Por arte de portada

Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In our 2023 podcasts, there have been a series of revelations about the complexity and unintended consequences related to drug access and affordability. This episode explores the essential underlying tension between the notion that affordability and access are deteriorating while science is advancing so rapidly. We interview Rachel King, CEO of Biotechnology Innovation Organization (BIO), to explore the priorities for the industry and how the challenges related to patient access and affordability could jeopardize innovation for patients today and in the future.

    Rachel King, CEO, BIO (Biotechnology Innovation Organization)

    John Crowley, Executive Chairman, Amicus Therapeutics

    James Robinson PhD, MPH, Chair, Health Policy and Management Division, Berkeley School of Public Health

    The Inflation Reduction Act

    Orphan Drug Act

    Orphan Cures Act

    PBM (pharmacy benefit management)

    Medicare Part D

    Step Therapy

    Cystic Fibrosis Foundation

    Therapies mentioned in this episode:

    • RNAi
    • Antisense
    • mRNA
    • Monoclonal antibody

    Email us at comments@prescriptionforbetteraccess.com.
    Find us on social media! We’re on X as @RX4BetterAccess, LinkedIn and YouTube.
    Más Menos
activate_primeday_promo_in_buybox_DT
Enfermedades Físicas Hygiene & Healthy Living Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles